Drug intelligence / Profile preview

Abarceo Pharma AD Program

Development stage: Preclinical
Lead developer: Abarceo Pharma
Modality: Small Molecules

Overview

Abarceo Pharma is developing a preclinical small molecule inhibitor targeting VDAC1 (voltage-dependent anion channel 1) oligomerization for the treatment of Alzheimer's disease. The mechanism of action involves preventing VDAC1 molecules from clustering together (oligomerization), a process linked to mitochondrial dysfunction, ATP leakage, and neuronal cell death. By inhibiting this overexpression-induced oligomerization, the therapy aims to restore mitochondrial energy production and cellular health in neurodegenerative contexts. The program is currently in the discovery and preclinical proof-of-concept stage.

Other names: VDAC1 inhibitor (Abarceo Pharma)

Targets

VDAC1 (Hexokinase 2–voltage-dependent anion channel 1 complex)

Beyond the preview

Go deeper on Abarceo Pharma AD Program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abarceo Pharma AD Program.

Explore the full profile